Amaya Lujambio Goizueta | Mount Sinai

Biography

Research Topics

Cancer, Epigenetics, Liver, Molecular Biology

Multi-Disciplinary Training Area

Cancer Biology [CAB], Immunology [IMM]

Research

Liver Cancer Biology

Amaia Lujambio´s research group studies mechanisms of liver cancer initiation and liver cancer maintenance. In particular, we are interested in how genetic alterations in cancer cells contribute to tumorigenesis, alter treatment response, and create vulnerabilities that may be targeted therapeutically. Furthermore, we are also interested in understanding the role of cellular senescence in liver cancer initiation. Our research interests involve the establishment of in vitro and in vivo systems for the study of liver cancer as well as the rational use of shRNA libraries to identify drug targets for the disease. We utilize sophisticated mouse models of cancer, RNAi technology, valuable human cancer samples, and genetic and epigenetic profiling as key tools. The ultimate goal is to improve our understanding of liver cancer biology and to identify novel strategies that can be exploited therapeutically.

Visit theLujambio Laboratory

Education

PhD, Spanish National Cancer Center (CNIO)

Postdoc, Cold Spring Harbor Laboratory (CSHL)

Postdoc, Memorial Sloan Kettering Cancer Center

Honors & Awards

2015

AASLD Pinnacle Research Award in Liver Diseases

AASLD

2010

EMBO Long Term Fellowship

EMBO

2010

Ph.D. Thesis Award

Universidad Autónoma de Madrid

2008

EMBO Short Term Fellowship

EMBO

2007

Eduardo Gallego Award

Fundación Francisco Cobos

2006

FPU Fellowship

Spanish Goverment

Publications

88

Publications

Selected Publications

NOTCH1 Drives Sexually Dimorphic Immune Responses in Hepatocellular Carcinoma. Katherine E. Lindblad, Romain Donne, Ian Liebling, Marina Barcena-Varela, Anthony Lozano, Marina Ruiz de Galarreta, Maxime Dhainaut, Nesteene J. Param, Bruno Giotti, Sarah Cappuyns, Takahiro Kodama, Yulei Wang, Alice O. Kamphorst, Alexander M. Tsankov, Amaia Lujambio. Cancer Discovery

Precision models in hepatocellular carcinoma. Marina Barcena-Varela, Satdarshan P. Monga, Amaia Lujambio. Nature Reviews Gastroenterology and Hepatology

Oncogenic role of PMEPA1 and its association with immune exhaustion and TGF-β activation in HCC. Marta Piqué-Gili, Carmen Andreu-Oller, Agavni Mesropian, Roger Esteban-Fabró, Marina Bárcena-Varela, Marina Ruiz de Galarreta, Carla Montironi, Iris Martinez-Quetglas, Sarah Cappuyns, Judit Peix, Ieva Keraite, Albert Gris-Oliver, Elisa Fernández-Martínez, Ezequiel Mauro, Miguel Torres-Martin, Jordi Abril-Fornaguera, Katherine E. Lindblad, Diether Lambrechts, Jeroen Dekervel, Swan N. Thung, Daniela Sia, Amaia Lujambio, Roser Pinyol, Josep M. Llovet. JHEP Reports

View All Publications

Video

Cancer Precision Medicine Retreat -- Session 5: Amaia Lujambio

Office Locations

Hess CSM Building Floor 6 Room 111

1470 Madison Ave

New York, NY 10029

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Lujambio Goizueta during 2024 and/or 2025. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

National Institute Of Health Office Of The Director/NIH/DHHS
Pioneering medicines
Yale University
La Caixa
University Of Pittsburgh
76bio
Hong Kong Baptist University
Mineco

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Lujambio Goizueta during 2024 and/or 2025. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

National Institute Of Health Office Of The Director/NIH/DHHS
Pioneering medicines
Yale University
La Caixa
University Of Pittsburgh
76bio
Hong Kong Baptist University
Mineco

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.